Description:FIELD OF THE INVENTION
The present invention relates to the field of biomedical engineering and regenerative medicine. More specifically, it pertains to the development of bio-scaffold materials designed for the treatment of lymphatic filariasis. The invention provides a regenerative and therapeutic scaffold system capable of stimulating lymphangiogenesis, supporting tissue regeneration, and enabling localized drug delivery for improved recovery of lymphatic function.
BACKGROUND OF THE INVENTION
Neglected tropical disease brought on by parasitic worms, lymphatic filariasis causes severe tissue destruction, lymphedema, and persistent lymphatic dysfunction. Limited effectiveness in restoring lymphatic function or reversing tissue damage is provided by present therapies including surgery and antiparasitic medications. Novel, localized, and regenerative treatment approaches are much needed. One interesting method to stimulate lymphangiogenesis and heal injured tissues is scaffold-based tissue engineering. Still, there are few ideal scaffold designs meant especially for lymphatic tissue regeneration. The objective of this work is to create biocompatible scaffolds that enhance lymphatic healing and provide continuous drug delivery to thereby improve treatment results.
Lymphatic filariasis is a neglected tropical disease caused by parasitic worms such as Wuchereria bancrofti, Brugia malayi, and Brugia timori. The infection, transmitted by mosquitoes, primarily affects the lymphatic system, resulting in severe conditions such as lymphedema, hydrocele, and elephantiasis. These symptoms cause chronic pain, deformity, and disability, drastically reducing quality of life.
The World Health Organization initiated the Global Programme to Eliminate Lymphatic Filariasis (GPELF) focusing on Mass Drug Administration (MDA) to reduce microfilariae levels and prevent transmission. Drugs like Diethylcarbamazine, Albendazole, and Ivermectin have been used extensively. However, while these medications effectively eliminate parasites, they fail to restore the lymphatic system’s structural and functional integrity once damaged.
The lack of regenerative treatment options has left patients with limited solutions that primarily control infection but cannot reverse tissue damage or chronic swelling. Surgical interventions can relieve symptoms but do not promote lymphatic regeneration or functional recovery. This presents a significant gap in therapeutic options for long-term treatment.
In recent years, scaffold-based tissue engineering has emerged as a promising field for regenerative therapy. Scaffolds can mimic the extracellular matrix (ECM), enabling cell attachment, proliferation, and new tissue formation. Several materials like collagen, fibrin, PLGA, and alginate have been investigated for vascular and lymphatic regeneration. Yet, none have been specifically optimized for lymphatic tissue regeneration in filariasis conditions.
The development of an optimized, biocompatible, and drug-loaded scaffold specifically targeting lymphatic vessel regeneration thus becomes a crucial innovation. It addresses the need for a dual-action solution that combines infection control and tissue repair, offering hope for patients suffering from chronic lymphatic dysfunction caused by filariasis.
US10695468B2: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.
US20180154011A1: The present invention provides Ligand-Drug Conjugates, Drug-Linkers, Linkers, and Ligand-Linker Conjugates comprising a self-stabilizing linker assembly component.
While current lymphatic filariasis treatments concentrate on parasite eradication, they do not restore injured lymphatic tissues. Scaffold-based materials address both infection management and long-term lymphatic dysfunction by enabling lymphangiogenesis, tissue healing, and localized drug delivery, therefore providing a regenerative solution—something existing treatments alone cannot accomplish.
SUMMARY OF THE INVENTION
This summary is provided to introduce a selection of concepts, in a simplified format, that are further described in the detailed description of the invention.
This summary is neither intended to identify key or essential inventive concepts of the invention and nor is it intended for determining the scope of the invention.
The current approach focuses on the fabrication of bio-scaffold materials which can effectively treat lymphatic filariasis diseases. This method is cost-effective, eco-friendly, and non-toxic, bio-active during the implantation.
To further clarify advantages and features of the present invention, a more particular description of the invention will be rendered by reference to specific embodiments thereof, which is illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail with the accompanying drawings.
The present invention discloses a scaffold-based therapeutic system for the treatment of lymphatic filariasis. The invention focuses on fabricating bioactive scaffolds capable of stimulating lymphangiogenesis, promoting tissue healing, and providing sustained localized drug delivery. The designed scaffold offers a regenerative platform to repair and reconstruct damaged lymphatic structures.
The scaffold comprises biocompatible and biodegradable materials that mimic the natural extracellular matrix, providing structural support for cell growth and vessel formation. It is designed to be eco-friendly, non-toxic, and bioactive during implantation, ensuring safe interaction with biological tissues.
The invention further integrates controlled drug release functionality to deliver antiparasitic or anti-inflammatory agents directly at the site of lymphatic injury. This sustained delivery enhances therapeutic efficacy and minimizes systemic side effects associated with oral or systemic medications.
In comparison to conventional drug therapies, this invention uniquely combines regenerative biomaterials and therapeutic delivery, enabling both structural repair and infection control simultaneously. The scaffold promotes new lymphatic vessel formation while maintaining a favorable healing microenvironment.
The invention offers a transformative approach to managing lymphatic filariasis by restoring physiological lymphatic function, reducing lymphedema, and enhancing tissue regeneration. By doing so, it addresses the long-standing limitation of existing treatments, which focus solely on parasitic eradication.
Overall, the proposed scaffold system represents a next-generation, localized, and regenerative therapeutic solution capable of revolutionizing the treatment outcomes for lymphatic filariasis.
BRIEF DESCRIPTION OF THE DRAWINGS
The illustrated embodiments of the subject matter will be understood by reference to the drawings, wherein like parts are designated by like numerals throughout. The following description is intended only by way of example, and simply illustrates certain selected embodiments of devices, systems, and methods that are consistent with the subject matter as claimed herein, wherein:
FIGURE 1: SYSTEM ARCHITECTURE
The figures depict embodiments of the present subject matter for the purposes of illustration only. A person skilled in the art will easily recognize from the following description that alternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles of the disclosure described herein.
DETAILED DESCRIPTION OF THE INVENTION
The detailed description of various exemplary embodiments of the disclosure is described herein with reference to the accompanying drawings. It should be noted that the embodiments are described herein in such details as to clearly communicate the disclosure. However, the amount of details provided herein is not intended to limit the anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the scope of the present disclosure as defined by the appended claims.
It is also to be understood that various arrangements may be devised that, although not explicitly described or shown herein, embody the principles of the present disclosure. Moreover, all statements herein reciting principles, aspects, and embodiments of the present disclosure, as well as specific examples, are intended to encompass equivalents thereof.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments. As used herein, the singular forms “a",” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises,” “comprising,” “includes” and/or “including,” when used herein, specify the presence of stated features, integers, steps, operations, elements and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components and/or groups thereof.
It should also be noted that in some alternative implementations, the functions/acts noted may occur out of the order noted in the figures. For example, two figures shown in succession may, in fact, be executed concurrently or may sometimes be executed in the reverse order, depending upon the functionality/acts involved.
In addition, the descriptions of "first", "second", “third”, and the like in the present invention are used for the purpose of description only, and are not to be construed as indicating or implying their relative importance or implicitly indicating the number of technical features indicated. Thus, features defining "first" and "second" may include at least one of the features, either explicitly or implicitly.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which example embodiments belong. It will be further understood that terms, e.g., those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
The current approach focuses on the fabrication of bio-scaffold materials which can effectively treat lymphatic filariasis diseases. This method is cost-effective, eco-friendly, and non-toxic, bio-active during the implantation.
The novelty of the scaffold design for lymphatic filariasis treatment is integrating regenerative biomaterials with targeted therapy to rebuild damaged lymphatic vessels. Unlike conventional antiparasitic drugs, these scaffolds restore lymphatic activity, offer sustainable medicines, and promote lymphangiogenesis. Providing a transformational response where no commercial regenerative therapy currently exists for lymphatic filariasis, this dual-action approach targets long-term tissue regeneration as well as infection control.
The invention relates to the fabrication of a bioactive scaffold structure engineered to treat lymphatic filariasis through tissue regeneration and sustained drug delivery. The scaffold is designed using biocompatible polymers, hydrogels, or natural biomaterials that emulate the extracellular matrix. Materials such as collagen, alginate, fibrin, or poly(lactic-co-glycolic acid) (PLGA) can be used individually or in combination to form a porous, biodegradable framework suitable for cell proliferation.
The scaffold’s structural configuration allows for interconnected pores to facilitate nutrient diffusion, lymphatic endothelial cell migration, and new vessel formation. The pore size and surface topology are optimized to encourage lymphangiogenesis while maintaining mechanical stability during tissue integration.
In one embodiment, the scaffold incorporates nanofibrous or hydrogel-based matrices that can be fabricated through electrospinning or freeze-drying techniques. The process parameters are adjusted to achieve high porosity and mechanical integrity required for implantation within lymphatic-damaged tissues.
The scaffold can be impregnated with therapeutic agents, including antiparasitic drugs, anti-inflammatory molecules, or growth factors, to promote localized and sustained release over a desired period. This controlled release enhances healing efficiency while minimizing the frequency of external drug administration.
During implantation, the scaffold interacts directly with the host tissue. Its biocompatible surface facilitates cell attachment, proliferation, and differentiation of lymphatic endothelial cells, leading to the formation of functional lymphatic vessels. The degradation rate of the scaffold is controlled to match tissue regeneration, ensuring gradual replacement by native tissue.
The bioactive components of the scaffold may include signaling molecules or natural extracts that further stimulate lymphangiogenesis and suppress inflammatory responses. The combination of structural and chemical cues accelerates the healing of damaged lymphatic tissues.
The scaffold may also serve as a carrier for stem or stromal cells to enhance regenerative outcomes. The inclusion of cellular components provides a synergistic effect, improving the formation of lymphatic capillaries and restoring lymphatic function.
Interconnection of components within the scaffold system ensures that drug diffusion channels and vascular growth paths align effectively. The integration of microchannels mimics the natural lymphatic architecture, supporting efficient lymph flow and drainage restoration.
Upon implantation, the scaffold begins to release the incorporated drug in a controlled manner. The local drug concentration remains within the therapeutic window, eliminating parasitic residues while simultaneously supporting tissue repair.
Over time, as the scaffold degrades, new tissue progressively replaces it. The newly formed lymphatic network restores lymph transport capacity, reducing edema and improving immune function. This biodegradable and bioactive mechanism eliminates the need for surgical removal after therapy.
The working methodology involves preparation of the scaffold material, integration of therapeutic agents, sterilization, and implantation into the affected site. Post-implantation, the regenerative and pharmacological processes synergistically operate to achieve comprehensive recovery.
The scaffold system can be tailored for patient-specific requirements based on the severity of lymphatic damage and anatomical variations. It provides a versatile platform adaptable to a range of biomaterial compositions and drug types.
The invention thus establishes an advanced therapeutic modality that bridges the gap between pharmacological treatment and regenerative medicine for lymphatic filariasis. It ensures long-term relief, tissue reconstruction, and restoration of lymphatic functionality.
, Claims:1. A scaffold-based therapeutic system for the treatment of lymphatic filariasis comprising a biocompatible and biodegradable scaffold structure configured for stimulating lymphangiogenesis, promoting tissue regeneration, and enabling sustained localized drug delivery.
2. The system as claimed in claim 1, wherein the scaffold is fabricated from natural or synthetic biomaterials selected from collagen, alginate, fibrin, or PLGA.
3. The system as claimed in claim 1, wherein the scaffold possesses interconnected pores facilitating nutrient diffusion, cell migration, and lymphatic vessel formation.
4. The system as claimed in claim 1, wherein the scaffold incorporates therapeutic agents selected from antiparasitic or anti-inflammatory drugs for controlled release.
5. The system as claimed in claim 1, wherein the scaffold further includes bioactive molecules or growth factors enhancing lymphangiogenesis and tissue recovery.
6. The system as claimed in claim 1, wherein the scaffold is designed for biodegradation synchronized with native tissue regeneration.
7. The system as claimed in claim 1, wherein the scaffold optionally carries stem or stromal cells for accelerating lymphatic tissue healing.
8. A method for treating lymphatic filariasis comprising implanting the scaffold as claimed in claim 1 at a site of lymphatic tissue damage, enabling localized drug release, and facilitating lymphatic vessel regeneration within the affected region.
9. The method as claimed in claim 8, further comprising allowing gradual degradation of the scaffold while promoting replacement by regenerated lymphatic tissue, thereby restoring lymphatic flow and function.
10. The method as claimed in claim 8, further comprising maintaining a sustained therapeutic concentration of the released agents at the target site, supporting infection control and continuous tissue repair.